Zocor/Zocor HP Indications/Uses

PATIENTS AT HIGH RISK OF CORONARY HEART DISEASE (CHD) OR WITH EXISTING CHD: In patients at high risk of CHD (with or without hyperlipidemia), i.e., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD, SIMVASTATIN (ZOCOR) is indicated to: Reduce the risk of total mortality by reducing CHD deaths; Reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, CHD death, stroke, or revascularization procedures); Reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or CHD deaths); Reduce the risk of stroke; Reduce the need for coronary revascularization procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); Reduce the need for peripheral and other non-coronary revascularization procedures; Reduce the risk of hospitalization for angina pectoris.
In patients with diabetes, SIMVASTATIN (ZOCOR) reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularization procedures, lower limb amputations, or leg ulcers).
In hypercholesterolemic patients with coronary heart disease, SIMVASTATIN (ZOCOR) slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.
PATIENTS WITH HYPERLIPIDEMIA: SIMVASTATIN (ZOCOR) is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, TG, and apolipoprotein B (apo B), and to increase HDL-C in patients with primary hypercholesterolemia including heterozygous familial hypercholesterolemia (Fredrickson type IIa), or combined (mixed) hyperlipidemia (Fredrickson type IIb), when response to diet and other nonpharmacological measures is inadequate. SIMVASTATIN (ZOCOR), therefore, lowers LDL-C/HDL-C and total-C/HDL-C ratios.
SIMVASTATIN (ZOCOR) is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia).
SIMVASTATIN (ZOCOR) is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
SIMVASTATIN (ZOCOR) is also indicated as an adjunct to diet and other non-dietary measures for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) to reduce elevated total-C, LDL-C and apo B.
PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: SIMVASTATIN (ZOCOR) is indicated as an adjunct to diet to reduce total-C, LDL-C, TG, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolemia (HeFH).